Table 1 Serum levels of AFP CEA, CA125 and CA19-9 in the study subjects
| Â | Gastric cancer(n=149) | Benign gastric disease(n=111) | Healthy control(n=124) | Statistic test |
|---|---|---|---|---|
Age (Year) | 59.1±11.5 | 52.9±17.4 | 53.0±9.6 | F=10.129, P=0.000 |
Gender (Male/Female) | 115/34 | 76/35 | 72/52 | χ 2=11.460, P=0.003 |
AFP (ng/mL) | 3.8±16.8 | 3.3±18.6 | 2.4±1.3 | F=0.332, P=0.718 |
CEA (ng/mL) | 10.5±27.8 | 1.9±2.8 | 1.4±0.9 | F=11.889, P=0.000 |
CA125 (U/mL) | 20.1±32.7 | 11.6±17.5 | 9.9±7.2 | F=7.895, P=0.002 |
CA19-9 (U/mL) | 22.8±39.1 | 11.4±18.7 | 9.5±4.7 | F=10.169, P=0.000 |
AFP Positive cases (%) | 7 (4.7) | 1 (0.9) | 1 (0.8) | χ 2=4.838, P=0.054 |
CEA Positive cases (%) | 26 (17.4) | 2 (1.8) | 0 (0.0) | χ 2=38.088, P=0.000 |
CA125 Positive cases (%) | 21(14.1) | 7 (6.3) | 1 (0.8) | χ 2=18.934, P=0.000 |
CA19-9 Positive cases (%) | 31(20.8) | 9 (8.1) | 0 (0.0) | χ 2=37.840, P=0.000 |
Combination Positive Cases (%) | 60 (40.3) | 14 (12.6) | 2 (1.6) | χ 2=74.443, P=0.000 |